Summers are becoming increasingly hotter, with 2023 marking the hottest year on record. The global average temperature has risen by 1.45°C compared to pre-industrial levels (1850-1900), nearing the 1.5°C target set by the Paris Agreement. In other words, the carbon reduction goals outlined by this global initiative, signed by over 130 countries, are facing a harsh reality.
Along with the challenges brought by extreme weather, species extinction is occurring at 100 to 1,000 times the natural rate. This threatens human access to food, clean water, and essential raw materials provided by various species. Some studies even predict that if this continues, Taiwan could lose its winters entirely by 2060.
Business leaders must recognize that profitability is no longer the sole objective; they must integrate financial performance with sustainability and embrace corporate citizenship. ESG has become a global imperative, particularly with the urgent goals of achieving net-zero emissions by 2050 and mitigating climate change. The government has passed the Climate Change Response Act, clearly defining the responsibilities and strategies for each ministry and agency. Additionally, the “Sustainable Development Roadmap for Listed Companies” has been introduced, mandating corporate disclosure of greenhouse gas emissions, carbon audits, and reduction measures—challenges that businesses can no longer avoid.
As a pioneering pharmaceutical company, OBI Pharma is committed not only to developing first-in-class and best-in-class novel drugs, but also to offering diverse therapeutic options aimed at eliminating the threat of cancer and opening a new chapter in healthcare. In 2023, OBI Pharma Taiwan made significant strides toward these goals. Aspiring to be more than just Taiwan’s premier innovative biotech firm, the company is determined to lead globally in cancer immunotherapy while continuously advancing across all ESG dimensions. By embedding sustainability at the core of its operations, OBI Pharma strives to contribute to a sustainable future for Taiwan, rooted in local engagement, social participation, robust governance, and a commitment to public welfare.
In 2024, OBI Pharma Taiwan made the following efforts:
